Can You Compete? Best Practices for Nonadvanced SM

Program Description

Don’t miss this Medical Jeopardy activity, designed to provide an informative, unique, and engaging educational approach to learning about nonadvanced systemic mastocytosis (SM)! Learners will watch a modified “Jeopardy” game, and each team will be led by our expert faculty contestants, with the didactic content presented as an explanation of the correct answer to each question. Topics covered will include pathophysiology, diagnosis, treatment paradigms, including the use of tyrosine kinase inhibitors, and real-world strategies for patient management and education. 

Target Audience

This activity is designed to educate clinical immunologists/allergists, dermatologists, gastroenterologists, pathologists, hematologists, and other specialist clinicians who diagnose or manage nonadvanced SM.

Educational Objectives

1. Discuss the causes and consequences of nonadvanced SM, focusing on potential clinical manifestations and the rationale for new targeted therapies
2. Differentially diagnose SM, including indolent disease, based on symptoms and appropriate use of laboratory and genetic testing
3. Describe recent clinical trial evidence and regulatory status for targeted treatment options in nonadvanced SM
4. Individualize therapy for patients with nonadvanced SM to reflect clinical evidence for efficacy and safety, patient-reported outcomes, and shared clinical decision-making

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

John M. Fahrenholz, MD: Consulting fees: Blueprint Medicines Corporation, Cogent Biosciences; Speakers bureaus:  Blueprint Medicines Corporation; Contracted research: Cogent Biosciences

Tracy I. George, MD: Consulting fees: Allakos Inc., Blueprint Medicines Corporation, BluPrint Oncology Concepts, Celgene Corporation, Incyte Corporation, UBC (United BioSource LLC); Contracted research: Blueprint Medicines Corporation, Celgene Corporation, Cogent Biosciences, Deciphera Pharmaceuticals, Inc., Incyte Corporation; all received by ARUP Laboratories

Matthew P. Giannetti, MD: Consulting, medical safety board: Cogent Biosciences, Inmagene; Research funding: Blueprint Medicines Corporation

Thanai Pongdee, MD: Contracted research: AstraZeneca, Blueprint Medicines Corporation, Cogent Biosciences, GlaxoSmithKline, Regeneron, Sanofi

The Integritas Communication planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.